MAZE FY 2024 Earnings — Maze Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

MAZEMaze Therapeutics, Inc.

$2B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$168M

Gross Profit

$168M100.0% margin

Operating Income

$58M34.4% margin

Net Income

$52M31.2% margin

EPS (Diluted)

$0.08

Cash Flow

Operating Cash Flow

$76M

Free Cash Flow

$75M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$241M

Total Liabilities

$44M

Stockholders' Equity

$197M

Cash & Equivalents

$197M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$168M	$0	—
Gross Profit	$168M	$0	—
Operating Income	$58M	-$99M	+158.4%
Net Income	$52M	-$100M	+152.0%